Mostrar o rexistro simple do ítem

dc.contributor.authorBertomeu-González, Vicente
dc.contributor.authorMoreno-Arribas, José
dc.contributor.authorEsteve-Pastor, María Asunción
dc.contributor.authorRoldán-Rabadán, Inmaculada
dc.contributor.authorMuñiz, Javier
dc.contributor.authorOtero García, Deborah
dc.contributor.authorRuiz-Ortiz, Martín
dc.contributor.authorCequier, Ángel
dc.contributor.authorBertomeu-Martínez, Vicente
dc.contributor.authorBadimón, Lina
dc.contributor.authorAnguita, Manuel
dc.contributor.authorLip, Gregory Y.H.
dc.contributor.authorMarín, Francisco
dc.date.accessioned2022-04-06T10:57:23Z
dc.date.available2022-04-06T10:57:23Z
dc.date.issued2020-10-16
dc.identifier.citationBertomeu-Gonzalez V, Moreno-Arribas J, Esteve-Pastor MA, Roldán-Rabadán I, Muñiz J, Otero García D, Ruiz-Ortiz M, Cequier Á, Bertomeu-Martínez V, Badimón L, Anguita M, Lip GYH, Marín F; FANTASIIA Study Investigators. Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry. Eur J Clin Invest. 2021 Apr;51(4):e13431.es_ES
dc.identifier.issn0014-2972
dc.identifier.urihttp://hdl.handle.net/2183/30406
dc.descriptionObservational studyes_ES
dc.description.abstract[Abstract] Background: Atrial fibrillation (AF) and peripheral artery disease (PAD) are common conditions that increase cardiovascular risk. We determined the association between PAD and prognosis in a cohort of real-world patients receiving oral anticoagulant therapy for nonvalvular AF. Methods: We prospectively included 1956 patients (mean age 73.8 ± 9.5 years, 44.0% women) receiving oral anticoagulant therapy for AF. Clinical characteristics were collected at baseline. Patients were followed for a period of 3 years. Survival analysis and multivariable regression analyses were performed to assess variables related to death, stroke, bleeding, myocardial infarction and major adverse cardiovascular events (MACE). Results: Patients with PAD (n = 118; 6%) exhibited higher rates of cardiovascular risk factors and cardiovascular diseases. After 3 years of follow-up, there were a total of 255 deaths (no PAD 233, vs PAD 22), 45 strokes (43 vs 2), 146 major bleedings (136 vs 10) and 168 MACE (148 vs 20). On univariate analysis, there was a higher risk of cardiovascular mortality (2.02%/year no PAD vs 4.08%/year PAD, P = .02), myocardial infarction (0.99%/year no PAD vs 2.43%/year PAD, P = .02) and MACE (3.18%/year no PAD vs 6.99%/year PAD, P < .01). There was no statistically significant association with these events after multivariable adjustment. Conclusions: In a large cohort of anticoagulated patients with AF, the presence of PAD represents a higher risk subgroup and is associated with worse crude outcomes. The exact contribution of the PAD independently of other cardiovascular diseases or risk factors requires further investigation.es_ES
dc.description.sponsorshipThe FANTASIIA registry was funded by an unconditional grant from Pfizer/Bristol-Myers-Squibb and by grants from the Instituto de Salud Carlos III (Madrid)-FEDER (RD16/11/00420, RD12/0042/0068, RD12/0042/0010, RD12/0042/0069, and RD12/0042/0063). The authors are supported by RD12/0042/0049 (RETICS) from ISCIII and PI13/00513/FEDER from ISCIII. Fundación Séneca (19245/PI/14), Instituto Murciano de Investigación Biosanitaria (IMIB16/AP/01/06).es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; RD16/11/00420es_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Acción Estratégica de Salud/RD12%2F0042%2F0068/ES/Enfermedades cardiovasculareses_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Acción Estratégica de Salud/RD12%2F0042%2F0010/ES/Enfermedades cardiovasculareses_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Acción Estratégica de Salud/RD12%2F0042%2F0069/ES/Enfermedades cardiovasculareses_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Acción Estratégica de Salud/RD12%2F0042%2F0063/ES/Enfermedades cardiovasculares
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Acción Estratégica de Salud/RD12%2F0042%2F0049/ES/Enfermedades cardiovasculares
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Programa Estatal de I+D+I Orientada a los Retos de la Sociedad/PI13%2F00513/ES/NUEVOS ANTICOAGULANTES ORALES EN LA FIBRILACIÓN AURICULAR
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.relation.urihttps://doi.org/10.1111/eci.13431es_ES
dc.rightsThis is the peer reviewed version of the article which has been published in final form at Wiley Online Library. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibitedes_ES
dc.subjectAtrial fibrillationes_ES
dc.subjectMortalityes_ES
dc.subjectPeripheral artery diseasees_ES
dc.subjectPrognosises_ES
dc.subjectStrokees_ES
dc.titlePeripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registryes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitleEuropean Journal of Clinical Investigationes_ES
UDC.volume51es_ES
UDC.issue4es_ES
UDC.startPagee13431es_ES


Ficheiros no ítem

Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem